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Abstract 
Rationale: Pendrin is encoded by SLC26A4 and its mutation leads to congenital hearing loss. Additionally, 
pendrin is up-regulated in inflammatory airway diseases such as chronic obstructive pulmonary disease, allergic 
rhinitis, and asthma. In this study, the effects of a novel pendrin inhibitor, YS-01, were investigated in an 
LPS-induced acute lung injury (ALI) mice model, and the mechanism underlying the effect of YS-01 was 
examined. 
Methods: Lipopolysaccharide (LPS, 10 mg/kg) was intranasally instilled in wild type (WT) and pendrin-null 
mice. YS-01 (10 mg/kg) was administered intra-peritoneally before or after LPS inhalation. Lung injury 
parameters were assessed in the lung tissue and bronchoalveolar lavage fluid (BALF). Pendrin levels in the BALF 
of 41 patients with acute respiratory distress syndrome (ARDS) due to pneumonia and 25 control (solitary 
pulmonary nodule) patients were also measured. 
Results: LPS instillation induced lung injury in WT mice but not in pendrin-null mice. Pendrin expression was 
increased by LPS stimulation both in vitro and in vivo. YS-01 treatment dramatically attenuated lung injury and 
reduced BALF cell counts and protein concentration after LPS instillation in WT mice. Proinflammatory 
cytokines and NF-κB activation were suppressed by YS-01 treatment in LPS-induced ALI mice. In BALF of 
patients whose ARDS was caused by pneumonia, pendrin expression was up-regulated compared to that in 
controls (mean, 24.86 vs. 6.83 ng/mL, P < 0.001). 
Conclusions: A novel pendrin inhibitor, YS-01, suppressed lung injury in LPS-induced ALI mice and our data 
provide a new strategy for the treatment of inflammatory airway diseases including sepsis-induced ALI. 










Acute lung injury (ALI), a common and severe 
pulmonary complication in critical illness, affects 
approximately 10 to 15% of patients hospitalized in 
the intensive care unit (ICU) [1]. Acute respiratory 
distress syndrome (ARDS), the most severe form of 
ALI, has a mortality rate of approximately 40%, 
despite modern ICU care [2,3]. Despite decades of 
research, treatment options for ARDS are limited and 
supportive care with mechanical ventilation remains 
the mainstay of ARDS management [4]. ARDS/ALI 
are characterized by the abrupt onset of hypoxemia 
with diffuse pulmonary infiltrates, and the 
accumulation of a protein-rich pulmonary edema that 
causes a reduction in lung compliance, alveolar 
collapse, and ventilation-perfusion mismatch [5]. 
Recent reports suggest that ion pump and channel 
functions are affected early in sepsis-induced 
ARDS [6] and that airway epithelial cells may be a 
valuable therapeutic target for ALI/ARDS treatment. 
Pendrin is encoded by SLC26A4 and acts as an 
anion exchanger that import Cl- and export bases such 
as HCO3-, I-, OH-, SCN-, and formate [7-10]. Pendrin is 
expressed in the inner ear and thyroid, and its 
mutation is associated with prelingual deafness 
(DFNB4) and Pendred syndrome [11,12]. Normal 
airway epithelium shows negligible pendrin 
expression. However, the expression of pendrin is 
strongly up-regulated in inflammatory airway 
diseases, such as chronic obstructive pulmonary 
disease, allergic rhinitis, asthma [13,14]; and enforced 
pendrin expression induces mucus overproduction 
with neutrophilic infiltration in mice airway epithelial 
cells [13]. Madeo et al. reported that SLC26A4 
mutation correlated with asthma resistance, although 
their results did not reach statistical significance due 
to the small number of patients [15]. Pendrin 
upregulation is also observed in primary airway 
epithelial cells when they are cultured with IL-4, 
IL-13, and IL-17A [8,13,16]. Nakagami et al. reported 
that pendrin-deficient mice had less allergen-induced 
airway hyper-reactivity and inflammation compared 
to control mice, and pendrin mRNA expression in 
human nasal epithelial cells increased in cases of 
common cold caused by rhinovirus [17]. Interestingly, 
pendrin-null mice show reduced lung inflammation 
in response to Bordetella pertussis [18]. This evidence 
indicates that pendrin is a critical protein in the 
pathogenesis of inflammatory airway disease. 
Recently, Dr. Verkman and his colleagues screened 
small molecules for pendrin inhibitors and showed 
that several pendrin inhibitor compounds 
significantly increased airway surface liquid thickness 
in cystic fibrosis patient bronchial epithelial cells 
expressing high levels of pendrin [19]. We also 
previously performed a cell-based high throughput 
screening for the identification of small-molecule 
pendrin inhibitors; the pendrin inhibitor we screened 
(YS-01) showed a strongly therapeutic effect in an 
OVA-induced allergy asthma murine model, where it 
inhibited pendrin/OSCN-/NF-κB-mediated airway 
inflammation [20]. Recently obtained data show that 
pendrin is also expressed in alveolar epithelia, and 
that administration of a non-specific anion exchanger 
inhibitor (methazolamide) attenuates the LPS- 
induced ALI phenotype [21]. 
Thus, we investigated whether the pendrin 
inhibitor YS-01 showed a therapeutic effect in an 
LPS-induced ALI mouse model and also examined 
the mechanism underlying the effects of YS-01. The 
findings of this study may provide a novel strategy 
for the treatment of inflammatory airway diseases 
including sepsis-induced acute lung injury. 
Materials and Methods 
Experimental animals 
Wild-type male C57BL/6J mice, 8–10 weeks of 
age and weighing 20– 24 g, were purchased from 
Orient Bio (Sungnam, Republic of Korea). Pendrin 
knock-out (KO) mice used in the experiment were 
provided by JY Choi, and transgenic NF-κB reporter 
and SPC-Cre-ERT2 mice used for in vivo optical 
imaging (IVIS) were provided by KT Nam and BC 
Cho of Yonsei university (Table S1 and Figure S1). 
LPS-induced ALI in a murine model 
LPS (Escherichia coli, O111: B4, Sigma) (10 
mg/kg) in 50 μL PBS was administered by intranasal 
(i.n.) inhalation. The control group was given 50 μL of 
sterile PBS intranasally. For the pre-treatment model, 
YS-01 (10 mg/kg) in 50 μL DMSO was administered 
intra-peritoneally (i.p) 1 h before LPS inhalation. For 
the post-treatment model, two doses of YS-01 at 6 and 
12 h after LPS inhalation were administered. The mice 
in the pretreatment group were euthanized and their 
lungs harvested 48 h after LPS inhalation. In the post- 
treatment group, euthanasia and sample collection 
occurred 24 h after the LPS administration. For the 
SCN- experiment, 50 μL of NaOH, NaHCO3, or 
NaSCN (100 mM) were administered intranasally 
after YS-01 treatment. PBS was administered in the 
same manner for the control group. Additional details 
on the methods for animal experiments are provided 
in an online data supplement. 
Human bronchoalveolar lavage fluid collection 
Forty-one patients with ARDS caused by 
pneumonia who underwent a bronchoalveolar lavage 
(BAL) were classified as the ARDS group. The 25 





patients who were admitted for evaluation of solitary 
pulmonary nodule (SPN) without evidence of 
pulmonary infection were classified as the control 
group at the Severance Hospital between May 2013 
and September 2015. 
Prior to bronchoscopy, subjects were sedated 
with midazolam and fentanyl. The bronchoscope was 
inserted and wedged into the mouth for the BAL. BAL 
was performed following a standardized protocol 
(ARDS group: bronchus of pulmonary lesion, Control 
group: opposite bronchus from lung mass) and 10 cc 
of BALF was acquired from each patient using 
approximately 30 mL of 0.9% sodium chloride. 
Demographic and clinical data, including age, gender, 
body mass index (BMI), comorbidities, BALF analysis, 
cause of pneumonia, and final diagnosis were 
obtained from each participant, as well as medical 
records. 
Statistics 
Statistical analysis was performed using Prism 
5.0 (GraphPad Software). Group comparisons were 
performed using a two-tailed Student’s t test to 
compare two groups, and a one-way ANOVA 
(followed by Bonferroni’s multiple comparison post- 
hoc test) to compare more than two groups. Data are 
expressed as the mean ± SD. P values of less than 0.05 
were considered statistically significant. 
Study approval 
All animal protocols were approved by the 
Institutional Animal Care Committee of the Medical 
College of Yonsei University (2016-0322). Human 
study protocols were reviewed and approved by the 
Institutional Review Board of Yonsei University 
Health Service, Severance Hospital, Seoul, Korea 
(ARDS group IRB No. 4-2013-0585, control group IRB 
No. 4-2014-1014). Written informed consent was 
obtained from patients or their guardians regarding 
BALF sample use. 
Results 
LPS-induced ALI absent in pendrin-null mice 
As expected, intranasal LPS instillation induced 
ALI in WT mice. The total cell count and protein 
concentration in bronchoalveolar lavage fluid (BALF) 
was markedly increased after LPS treatment (Figure 
1A). Lung histology also showed leukocyte 
infiltration and lung injury in WT mice (Figure 1B). In 
contrast, LPS did not increase cell count or protein 
concentration in pendrin-null mice (Figure 1C). Lung 
histology also revealed a lack of leukocyte infiltration 
and lung injury in pendrin-null mice after LPS 
treatment (Figure 1D). The mean body weight change 
after 48 hours of LPS instillation was more 
pronounced in WT mice than in pendrin-null mice 
(-3.38 g vs. -1.75 g, P < 0.01, Figure 1E). Immunoblot 
analysis of lung tissue lysates showed that pendrin 
protein expression was increased after LPS treatment 
compared to the vehicle control (Figure 1F). These 
results suggested that pendrin has an essential role in 
the development of LPS-induced ALI. 
The effect of a novel pendrin inhibitor (YS-01) 
in human alveolar epithelial cells 
In our previous study [20], a novel pendrin 
inhibitor, YS-01 was identified by the high- 
throughput screening of 54,400 synthetic compounds. 
YS-01 potently inhibited Cl-/I-, Cl-/SCN-, Cl-/HCO3-, 
and Cl-/OH- exchange activity in naso-tracheal 
epithelia [20]. In this study, we showed that YS-01 
potently inhibited the Cl-/SCN- exchange activity of 
pendrin (IC50 = 4.7 ± 0.82 µM) in pendrin-transfected 
human alveolar epithelial cells (hAEC) in a 
dose-dependent manner (Figure 2B). Our previous 
study showed that long-term treatment of YS-01 
significantly reduced the protein expression level of 
pendrin without changing the mRNA expression level 
of pendrin [20]. We also investigated the effect of LPS 
and YS-01 on protein and mRNA levels of pendrin in 
hAEC. Western blot analysis and densitometry 
showed that pendrin expression was increased after 
LPS treatment and suppressed after YS-01 treatment 
(Figure 2C). Meanwhile, LPS treatment significantly 
increased mRNA levels of pendrin, but YS-01 did not 
alter the mRNA levels of pendrin in hAEC (Figure 
2D). Previous studies have shown that upregulation 
of pendrin can activate NF-κB by increasing hypo-
thiocyanite (OSCN−) production via upregulation of 
dual oxidase (Duox1/Duox2) in airway epithelium of 
allergic inflammation [22]. Real-time PCR analyses 
showed that LPS treatment significantly increased the 
mRNA levels of Duox2, and YS-01 did not alter 
mRNA levels of Duox2 (Figure 2E). 
Pendrin inhibition attenuated LPS-induced 
ALI in mice 
To investigate the protective function of YS-01 in 
an LPS-induced ALI mouse model, mice were treated 
with YS-01 one hour before LPS intranasal instillation 
and euthanized 48 hours after LPS administration 
(Figure 3A). YS-01 (10 mg/kg) pre-treated mice 
displayed decreased BALF total cell count and protein 
concentration levels compared to vehicle treated mice 
(Figures 3B and 3C). YS-01 pre-treatment also 
significantly reduced the lung injury score compared 
to vehicle-treated mice, where leukocyte infiltration 
occurred after LPS exposure (Figures 3D and 3E). To 
determine whether YS-01 treatment was effective after 
LPS injury, mice were treated with YS-01 at 6 and 12 h 





after LPS intranasal instillation, and then euthanized 
24 hours after LPS administration (Figure 3F). YS-01 
treatment after LPS instillation significantly reduced 
BALF total cell count and protein concentration, as 
well as lung injury score, consistent with the results of 
the YS-01 pre-treatment experiment (Figures 3G-I). 
SCN- instillation triggered LPS-induced ALI in 
the presence of a pendrin inhibitor and in 
pendrin-null mice 
To measure SCN- transport, we used human 
nasal epithelial (HNE) cells using air-liquid interface 
culture. The SCN- concentration at the apical surface 
was increased by LPS exposure and inhibited by 
YS-01 significantly (Figure 4A). To identify the 
underlying therapeutic effect mechanism of YS-01 in 
LPS-induced ALI, we supplied the anions secreted by 
pendrin (OH-, HCO3-, and SCN-). Intranasal 
application of NaSCN (50 μL of 100 mM) blocked the 
protective effects of YS-01 in LPS-induced ALI; BALF 
total cell count and lung injury score were increased 
compared to the group treated with LPS alone. 
However, administration of NaOH and NaHCO3 did 
not change the effect of YS-01 in LPS-induced ALI 
mice (Figures 4B and 4C). Histological analysis also 
revealed that the protective effect of YS-01 on 
inflammatory cell infiltration and lung injury after 
LPS administration was abolished by NaSCN 
administration (Figure 4D). More interestingly, 
simultaneous application of NaSCN with LPS 
induced robust lung injury in pendrin-null mice, 
whereas administration of LPS alone did not induce 
ALI (Figure 4E). These data strongly indicate that the 
therapeutic effect of YS-01 results from the SCN- 
transport function inhibition of pendrin. 
Pendrin inhibitor blocked the NF-kB pathway 
and decreased inflammatory cytokines in an 
LPS-induced ALI mouse model 
We further dissected the signaling pathway by 
which YS-01 acts in an LPS-induced ALI model using 
NF-κB reporter/SPC-Cre-ERT2 mice. Quantitative 
fluorescence was determined using in vivo optical 
imaging (IVIS) images of mouse lungs that were 
aseptically removed immediately prior to imaging. 
Fluorescence in the excised lungs was increased after 
 
 
Figure 1. Pendrin deficiency attenuated LPS-induced lung injury in mice. Wild type (WT) and pendrin-null (Pds-/-) mice were intranasally administered LPS (10 mg/kg) 
or vehicle (PBS). (A) Total bronchoalveolar lavage (BAL) cell counts and BAL protein concentration were analyzed 48 h after LPS or PBS administration in WT mice. (B) 
Representative images of H & E staining of lung tissue 48 h after LPS or PBS administration (×400), scale bars: 50 µm. (C) Total BAL cell counts and BAL protein concentration 
were analyzed 48 h after LPS or PBS administration in pendrin-null mice. (D) Representative images of H & E staining of lung tissue 48 h after LPS or PBS administration (×400), 
scale bars: 50 µm. (E) Mice body weight changes. (F) Representative western blot analysis and densitometry of pendrin in lung lysates of LPS untreated and treated WT mice. Data 
provided are the mean ± SEM (n = 6-8 mice per group), *P < 0.05, **P < 0.01, ***P < 0.001 analyzed by Student’s unpaired two-tailed t test. 





LPS treatment, which was suppressed by YS-01 
(Figures 5A and 5B). These results suggested that 
NF-κB activation in LPS instilled mice was suppressed 
by YS-01. Immunoblot analysis showed that the 
NF-κB pathway was associated with YS-01 action. 
Phospho-IκB protein expression, which represented 
NF-κB activation, was increased after LPS 
administration, and YS-01 treatment before LPS 
significantly reduced phospho-IκB expression 
(Figures 5C and 5D). Pendrin mRNA levels 
significantly increased after LPS and were decreased 
by YS-01 (Figure 5E). The levels of cytokines including 
IL-1ß, tumor necrosis factor-α, and macrophage 
inflammatory protein (MIP)-2 were significantly 
increased after LPS administration compared to PBS 
(Figures 5F-I). IL-6 tended to be increased, relative to 
PBS, although the difference was statistically 
insignificant. In contrast, levels of pro-inflammatory 
cytokines decreased in YS-01 pre-treated mice 
compared to those that received vehicle (DMSO) 
treatment after LPS administration (Figures 5F-I). 
Pendrin levels in human BALF were increased 
in patients with pulmonary infection 
To translate in vitro and in vivo findings to 
human disease, we measured BALF pendrin protein 
expression in patients with ARDS caused by 
pneumonia (ARDS group, n = 41) and patients with a 
solitary pulmonary nodule (SPN) but no infection 
(control group, n = 25). Patient clinical characteristics 
are shown in Table 1. Mean age was not significantly 
different between the control and ARDS groups (63.8 
vs. 65.9, p = 0.517) and males were predominant in 
both groups (80% vs. 78%, p = 0.851). Among the 
ARDS patients, the median length of hospital stay was 
36 days, and the 28-day mortality rate was 24.4% 
(Table 1). Detailed clinical information of study 
patients can be found online in Table S2. Pendrin level 
was significantly elevated in the BALF of ARDS 
patients (n = 41) compared to that of the control 
subjects (n = 25) (mean, 24.86 vs. 6.83 ng/mL, P < 
0.001) (Figure 6). 
 
 
Figure 2. Novel pendrin inhibitor (YS-01) blocked pendrin activity in human alveolar epithelial cells. (A) Chemical structure of YS-01 pendrin inhibitor. (B) 
Inhibitory effect of YS-01 on human wild-type pendrin-mediated Cl-/SCN- exchange activity in hAEC expressing human pendrin (mean ± SEM., n = 10). Indicated concentrations 
of YS-01 were pretreated for 10 min. Dose-response summary (right). (C) Representative western blot analysis of pendrin (PDS) in human alveolar epithelial cells (hAEC) and 
relative band intensity (mean ± SEM., n = 3). (D) PDS mRNA levels were determined by real-time quantitative PCR in hAEC (mean ± SEM., n = 3). (E) DUOX2 mRNA levels were 
determined by real-time quantitative PCR in hAEC (mean ± SEM., n = 3~4). *P < 0.05, **P < 0.01 analyzed by Student’s unpaired two-tailed t-test. 






Figure 3. YS-01 suppressed the LPS-induced acute lung injury phenotype in mice. (A) YS-01 (10 mg/kg) was intraperitoneally injected 1 h before LPS treatment. (B) 
BALF total cell count. (C) BALF protein concentration. (D) Representative images of H&E lung tissue staining (×400), scale bars: 50 µm. (E) Lung injury scores. (F) YS-01 (10 
mg/kg) was intraperitoneally injected at 6 and 12 h after LPS inhalation. (G) BALF total cell count. (H) BALF protein concentration. (I) Lung injury scores. Data provided are the 
mean ± SEM (n = 10-12 mice per group), ***P < 0.001, analyzed by one-way ANOVA with Bonferroni’s post hoc test. 
 
Figure 4. SCN- triggered LPS-induced lung injury in the presence of YS-01 or pendrin-null mice. (A) Effect of YS-01 on SCN- transport in HNE cells (mean ± SEM 
(n = 5 per group). (B) BALF total cell count. LPS (10 mg/kg, i.n.), YS-01 (10 mg/kg, i.p), NaOH (100 mM, i.n.), NaHCO3 (100 mM, i.n.) and NaSCN (100 mM, i.n.) were treated 
in WT mice. (C) BALF protein concentration. (D) Lung injury score. Representative lung tissues stained with H & E (right) (×400), scale bars: 50 µm. (E) BALF protein 
concentration in pendrin-null mice. NaSCN (100 mM, i.n.) was applied to the LPS treated pendrin-null mice. Representative mouse BALF cytospin stained with Diff-Quik Stain. 
Inflammatory cells, especially neutrophils (red arrows) were increased after LPS + NaSCN exposure compared to LPS or NaSCN alone (right). Black arrows represent 
macrophages (×200), scale bars: 100 µm. Data provided are the mean ± SEM (n = 5-6 per group), *P < 0.05, **P < 0.01, ***P < 0.001, analyzed by one-way ANOVA with 
Bonferroni’s post hoc test. 






Figure 5. YS-01 blocked the NF-κB pathway and reduced the levels of proinflammatory cytokines in LPS-induced acute lung injury. (A) Representative 
images of lungs from NF-κB/SPC-Cre mice exposed to LPS (10 mg/kg) and treated with either YS-01 (10 mg/kg) or a vehicle. IVIS image fluorescence is presented as the radiant 
efficiency. (B) Average fluorescence was quantified by region of interest analysis using Living Image software. Data provided are the mean ± SEM (n = 9–10 mice per group). (C) 
Representative western blot analysis in lung lysate. (D) Relative protein levels were measured by densitometry for pendrin and phospho-IκB. (means ± SEM, n = 6 per group). (E) 
Pendrin mRNA levels were determined by real-time quantitative PCR in lung tissue (means ± SEM, n = 11 per group). (F-I) IL-1β, CXCL2/MIP-2, IL-6 and TNF-α levels were 
measured by ELISA in lung tissue lysates. Data provided are the mean ± SEM (n = 7–8 mice per group), *P < 0.05, **P < 0.01, **P < 0.001, analyzed by one-way ANOVA with 
Bonferroni’s post hoc test. 
 
Table 1. Clinical characteristics of study patients 
  Control (n = 25)  ARDS* (n = 41) P 
Age, years, mean ± SD 63.8 ± 9.7 65.9 ± 13.6 0.517 
Gender, male, N (%) 20 (80.0) 32 (78.0) 0.851 
BMI (kg/m2), mean ± SD 24.5 ± 4.3 22.6 ± 3.0 0.040 
ICU admission, N (%) 0 41 (100) - 
Intubation/ARDS, N (%) 0 41 (100) - 
P/F ratio, mean ± SD − 157.3 ± 52.8 - 
Bacteremia, N (%) 0 9 (22.0) - 
Length of stay, d, median (IQR) 2 (1-2) 36 (26-57) - 
28-day mortality, N (%) 0 10 (24.4) - 
In-hospital mortality, N (%) 0 28 (68.3) - 
Pendrin level, ng/mL, mean ± SD  6.83 ± 6.91 24.86 ± 9.28 <0.001 
Values are presented as the mean±SD, median (interquartile range, IQR), or 
number (%); 
*ARDS due to pneumonia; 
Abbreviations: BMI, body mass index; ICU, intensive care unit; ARDS, acute 




Emerging evidence strongly suggests that 
pendrin is a key protein in the development of airway 
inflammatory diseases including asthma, chronic 
obstructive pulmonary disease, and rhinitis [13,23]. 
We demonstrated that the pendrin expression level in 
LPS-treated mouse airways increased. Moreover, we 
showed that LPS-induced ALI did not develop in 
pendrin null mice, which strongly indicated the 
critical role of pendrin in ALI pathogenesis. This is 
consistent with a recent report that showed pendrin 
expression was enhanced in LPS-induced ALI, and a 
non-specific pendrin inhibitor attenuated ALI in 
mice [21]. This evidence encouraged us to develop a 
pendrin inhibitor as a novel drug for ALI treatment. 
We screened more than 54,400 small molecules and 
found a specific pendrin inhibitor (YS-01) that did not 
affect other ion transports, such as Cystic fibrosis 
transmembrane conductance regulator (CFTR) and 
calcium-activated chloride channel (CaCC) [20]. 
Pendrin expression was upregulated by LPS 
treatment in human alveolar epithelial cell culture, 
which was effectively suppressed by YS-01. Figures 
2C-2D show that treatment of YS-01 significantly 
reduced the protein expression of pendrin without 
changing mRNA expression in hAEC. These results 
suggested that YS-01 decreased the protein stability of 
pendrin and consistent with our previous results in 





human nasal epithelial cells [20]. Interestingly, YS-01 
reduced both protein and mRNA levels of pendrin in 
the animal model of LPS-induced lung injury (Figures 
5D and 5E). The reduction of pendrin mRNA 
expression levels in YS-01-treated mice may be due to 
the decreased inflammatory signals by inhibition of 
pendrin. Decreased pendrin mRNA expression and 
destabilization of pendrin protein by YS-01 may 
enhance the reduction of pendrin protein in vivo. 
Surprisingly, YS-01 almost completely prevented the 
development of LPS-induced ALI in mice. 
Furthermore, administration of YS-01 after LPS 
treatment attenuated lung injury in mice, which 
indicated that the clinical therapeutic window of 
pendrin inhibitors is wide enough to include post-ALI 
periods. We demonstrated that pendrin expression in 
BALF from pneumonia patients and LPS-treated 
mouse airways increased, which strongly suggested a 
high possibility for the clinical application of pendrin 
inhibitors in inflammatory airway disease. 
 
 
Figure 6. Pendrin levels of human BALF. Patients with ARDS caused by 
pneumonia displayed increased pendrin levels compared to the control patients 
(without infection). Pendrin levels were measured from human BALF supernatant by 
ELISA (Control n = 25, ARDS n = 41). *P < 0.05, **P < 0.01, ***P < 0.001, analyzed by 
Student’s unpaired two-tailed t test. 
 
The role of pendrin and the mechanism 
underlying the therapeutic effects of YS-01 in the ALI 
model are unclear. We focused on the Cl-/SCN- 
exchange activity of pendrin and hypothiocyanite 
(OSCN-), which is synthesized from SCN- transported 
via several anion transporters (including pendrin) by 
lactoperoxidases in the airway epithelia. OSCN- is 
known to be part of an important innate defense 
system against microbes in the airways [24,25] and 
also induces airway inflammation in airway epithelia. 
Recent studies show that IL-4 upregulates the 
Cl-/SCN- exchange activity of pendrin and increases 
OSCN− production, which results in NF-κB activation 
and induces airway inflammation in a murine allergic 
asthma model [22,26]. We showed that the therapeutic 
effect of YS-01 on lung injury disappeared when 
NaSCN was added into the airways of mice. NaSCN 
application also induced lung injury even in pendrin 
null mice, whereas LPS-induced ALI had not 
developed. These data indicate that airway surface 
SCN- transported by pendrin is an essential 
component for LPS- induced airway inflammation. 
NF-κB is a crucial transcription factor for 
inflammatory responses in airways [27,28] and its 
inhibition attenuates ALI in vivo [29,30]. We also 
observed that YS-01 inhibited LPS-induced NF-κB 
activation and subsequent cytokine production in a 
murine ALI model and alveolar epithelia. 
Collectively, our data indicated that the pendrin 
inhibitor mode of action resulted from YS-01 blocking 
the transepithelial transport of SCN-, and 
subsequently inhibiting OSCN- generation and NF-κB 
activation. This resulted in the suppression of 
proinflammatory cytokine production (Figure 7). This 
is a very similar mode of action to that uncovered in 
our asthmatic mouse model, where pendrin inhibitors 
attenuated OVA-induced allergic airway 
inflammation by inhibiting the pendrin/OSCN-/ 
NF-κB cascade [20]. However, if we take into account 
the previous reports [31,32], which showed that LPS 
can also activate NF-κB via the TLR4/MyD88 
pathway, the reason for YS-01 almost completely 
suppressing LPS-induced ALI remains unknown. 
However, the deficiency of ALI phenotypes triggered 
by NaSCN in pendrin null mice strongly indicates 
that pendrin-mediated OSCN- dominantly activates 
the NF-κB cascade in an LPS-induced ALI model. 
Although critical care for ALI patients has 
improved, ALI/ARDS mortality remains high and 
there are limited options for the medical treatment of 
ALI/ARDS. Because YS-01 showed a strong 
therapeutic effect on our ALI murine model, pendrin 
could be a novel target for the medical treatment of 
ALI/ARDS. It is promising that pendrin expression 
was upregulated in pneumonia patient BALF, which 
increases the potential clinical therapeutic benefit of a 
pendrin inhibitor for ALI/ARDS. However, there are 
still several issues requiring resolution before the 
clinical application of pendrin as a drug for ALI/ 
ARDS treatment. First of all, the systemic adverse 
effect of pendrin inhibitors must be ruled out in areas 
where pendrin is expressed, including the inner ear, 
thyroid, and kidney. Although we can rule out 
hearing loss and hypothyroidism in a mouse model 
based on our preliminary studies [20], we must 
examine possible systemic side effects more 
thoroughly. We can also avoid potential systemic side 
effects by the local administration of pendrin 
inhibitors in patients with ALI. Another important 
issue for the development of pendrin inhibitors as a 
drug for ALI treatment is the specificity of YS-01 on 
pendrin. Our previous study [20] showed that YS-01 





weakly stimulates SLC26A3 (DRA) and SLC26A6, so 
it can exert a biological effect in the intestine and 
kidney. We need to find more specific YS-01 
analogues through additional structure-activity 
relationship analysis. Nevertheless, YS-01 is 
chemically stable with low cytotoxicity and works at a 
nanomolar level; it is an excellent compound for the 
further development of a final candidate for clinical 
trials. 
Although our current study suggests that the 
inhibition of SCN- transport by pendrin inhibitor is a 
crucial mechanism, we cannot demonstrate the 
difference in SCN- concentration in mice airway space. 
Further study is needed to figure out a proper method 
to quantify SCN- or OSCN- levels directly. Despite 
such limitations, we demonstrated that pendrin is 
essential for LPS-induced ALI, and a small molecule 
(YS-01) that inhibits pendrin strongly suppressed 
LPS-induced ALI. Our study indicates that pendrin 
inhibitors are a promising new drug class for ALI 
treatment. 
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